Thus, we could assume that sclerostin and DKK1 levels are affected by thyroid status, indicating involvement in pathophysiological processes activated in GD via the canonical Wnt pathway; however, those changes are reversible with the timely initiation of ATD therapy. This evidence concerns the gene DKK1 and Jeune syndrome.